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Efforts to construct therapeutically useful models of biological systems require large and diverse sets
of data on functional connections between their components. Here we show that cellular responses
to combinations of chemicals reveal how their biological targets are connected. Simulations of
pathways with pairs of inhibitors at varying doses predict distinct response surface shapes that are
reproduced in a yeast experiment, with further support from a larger screen using human tumour
cells. The response morphology yields detailed connectivity constraints between nearby targets,
and synergy profiles across many combinations show relatedness between targets in the whole
network. Constraints from chemical combinations complement genetic studies, because they probe
different cellular components and can be applied to disease models that are not amenable to
mutagenesis. Chemical probes also offer increased flexibility, as they can be continuously dosed,
temporally controlled, and readily combined. After extending this initial study to cover a wider
range of combination effects and pathway topologies, chemical combinations may be used to refine
network models or to identify novel targets. This response surface methodology may even apply to
non-biological systems where responses to targeted perturbations can be measured.
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Introduction
Living organisms are built of interacting components, whose
function and dysfunction can be described through dynamic
network models (Davidson et al, 2002). Systems Biology
involves the iterative construction of such models (Ideker et al,
2001), and may eventually improve the understanding of
diseases using in silico simulations. Such simulations may
eventually permit drugs to be prioritized for clinical trials,
reducing potential risks and increasing the likelihood of
successful outcomes.
Owing to the staggering complexity of biological systems,
efforts to model them require large and diverse sets of data on
connections between components and responses to system
perturbations. Among the most advanced models are those
developed for baker’s yeast, Saccharomyces cerevisiae (Zhang
et al, 2005), which are built upon protein–DNA (Lee et al,
2002) and protein–protein (Ho et al, 2002) associations,
supplemented by correlated changes in gene expression
(Hughes et al, 2000) or protein abundances (Gygi et al,
1999) under differing conditions. Information gleaned from
targeted synergies, such as paired mutations (Tong et al,
2004) and gene–drug interactions (Parsons et al, 2004), have
proven to be especially useful for revealing functional
connections between components. Chemical combinations
also show promise, and a proliferation experiment with
yeast mutants in the presence of probe mixtures (Haggarty
et al, 2003) has found that chemical profiles correlate with
genetic similarity. This potential is confirmed by recent
experiments using antibacterial combinations (Yeh et al,
2006) that show a relationship between synergy and chemical
target relatedness.
Combination responses to varying concentrations of com-
pounds provide a more detailed look at synergistic perturba-
tions. Combination therapies have been used increasingly over
the past century, and comprehensive reviews (Berenbaum,
1989; Greco et al, 1995) describe the experimental designs and
combination analyses employed. Combinations of two or more
agents can be tested using either exhaustive or efficient
designs (Carter and Wampler, 1986), and the most widely used
is the factorial design (also ‘checkerboard’ or ‘dose matrix’)
where combinations are tested in all possible permutations of
serially diluted single agent doses (Figure 1). A dose-matrix
experiment comprehensively samples the underlying response
surface with few assumptions about its shape. We have
previously reported an approach for high-throughput dose-
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matrix screening of chemical combinations (Borisy et al, 2003;
Keith et al, 2005; Zimmermann et al, 2007) in cell-based assays
that preserve disease-relevant biological connections. Such
screens yield a variety of response surfaces, with distinct
shapes for combinations that work through different known
mechanisms, suggesting that combination effects may contain
information on the nature of functional connections between
drug targets.
The past study of drug combinations has focused mainly on
the question of whether a combination is more potent than
equally effective doses of its constituents (Greco et al, 1995).
Synergy over this level is especially important when justifying
clinical uses, as it defines the point at which the combination
can provide additional benefit over simply increasing the dose
of either agent. This most widely used dose additivity model
(Loewe, 1928) represents the expected response if both agents
are actually the same compound. In that case, a slice through
the response surface at any chosen iso-effect level (or
‘isobole’) should show a linear relationship between the doses
of the two agents. For example, if 50% inhibition (I¼T/U for
treated and untreated samples) is achieved separately by 1 mM
of drug A or 2mM of drug B, a combination of 0.5 mM of A and
Figure 1 The morphology of cell-based dose-matrix responses to chemical combinations differs between mechanisms. Data for two synergistic antibacterial
combinations using a methicillin-resistant Staphylococcus aureus strain are shown in three-dimensional projections. In Augmentins (A), clavulanate disables a
bacterial defence against penicillin drugs, whereas both agents in Bactrims (B) inhibit enzymes in folate metabolism. The mechanisms of action differ between the two
combinations, as do the shapes of their response surfaces. Dose-matrix response surfaces show the inhibition of growth (1treated/untreated) for each pairwise
permutation of the serially diluted single agent doses. The 2D maps (C, D) show a top-down view of the surface, using the same colours for inhibition levels, to better
display mathematical descriptions of the shape without obscuring any data, and permit many matrices to be shown together with clarity.
Chemical combinations and target connectivity
J Leha´r et al
2 Molecular Systems Biology 2007 & 2007 EMBO and Nature Publishing Group
1mM of B should also inhibit by 50%. Formally, the response at
combined concentrations X,Y is the inhibition ILoewe that
satisfies (X/XI)þ (Y/YI)¼1, where XI and YI are the single
agent effective concentrations that produce ILoewe. Deviations
from Loewe additivity are usually quantified using the
combination index (Chou and Talalay, 1983) CI¼(X/XI)þ
(Y/YI), which is essentially a ratio of total effective drug dose
(combination versus single agents) required to achieve a given
effect level. Loewe additivity is experimentally demanding
because determining the effective concentrations requires
well-sampled single agent curves. Moreover, the dose-additive
constraint is not in closed form; so Loewe additive response
surfaces generally must be computed using iterative root
finding (Berenbaum, 1985). The other frequently used
reference model is Bliss independence (Bliss, 1939), which is
the expectation (multiplicative probabilities) for independent
yet competing elimination agents, like bullets aimed at a
limited set of targets. For inhibitions, IMult¼IXþ IY–IXIY, where
IX and IYare the single agent inhibition levels at concentrations
X and Y. Although this model is of questionable relevance to
drugs in biological settings, Bliss independence has often been
favoured because it can be directly calculated from minimally
sampled experiments without single agent response curve
interpolation or iterative root finding. A third useful reference
is the highest single agent (HSA) model, or Gaddum’s
non-interaction (Berenbaum, 1989), where the expected
combination effect is simply the maximum of the single agent
responses at corresponding concentrations.
The relationship between combination effects and drug
mechanism has been intuitively recognized for some time, but
attempts to theoretically model this association (Ashford and
Cobby, 1974; Harrap and Jackson, 1975; Jackson, 1993) have
proven problematic. These studies simulated a branched
metabolic pathway as a system of linked ordinary differential
equations, and the final reaction velocity was calculated in
response to varying concentrations of inhibitors targeting
different modelled enzymes. Synergy over Loewe additivity
was assessed for each pair of enzyme inhibitors by computing
simulated dose matrices and reporting the smallest combina-
tion index at 50% inhibition. However, these efforts could not
unambiguously predict synergy or antagonism, because it was
possible to generate any combination index for most inhibitor
pairs by varying one or more of the many kinetic parameters
in the pathway model.
We approached the problem by focusing not just on the
presence or absence of synergy relative to some reference
level, but by using a set of shape models to characterize the
morphology of full response surfaces. Here we show that there
is a clear relationship between dose-matrix response shape for
a combination and the connectivity of its targets (the type
of connection between them), using simulated pathways
and combination experiments. The simulations were used to
define a reference set of shape models that represent
connectivity-related responses, and the experiments demon-
strated that the shapes predicted by the simulations do indeed
occur in biological settings. We also use the data to show that
the synergy profile produced by a drug across many combina-
tions in a screen depends on the drug’s mechanism, and can
also be used to infer connectivity relationships between drug
targets.
Results
We considered four models for combination effect morphology
(Figure 2 and Materials and methods) that reflect historical
combination analyses and that represent many of the
responses observed in our therapeutic combination screens.
The HSA model describes a simple superposition of the single
agent curves. Loewe additivity (Loewe, 1928) is the drug-with-
itself reference to represent dose-additive pairings. The ‘Bliss
boosting’ model extends Bliss Independence (Bliss, 1939) to
allow variable boosts in effect at high concentrations. Finally,
the ‘Potentiation’ model describes combinations like Bactrims
(Figure 1), where one agent’s curve is shifted with a power-law
slope and superposed on the enhancer’s own activity. These
models are not an optimally designed basis set of shape
descriptors because they are not orthogonal (they produce
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Figure 2 Combination response shape models that describe many of the
observed response morphologies. Each model (shown using the same colour
scale as Figures 1 and 3) is used to calculate an expected combination effect
Imodel at any concentration X,Y, based on the single agent response curves.
(A) HSA is a superposition of the X and Y single agent responses, calculated
from the inhibitions IX at X and IY at Y. (B) Loewe additivity (Loewe, 1928) is the
drug-with-itself reference for synergy, where ILoewe at X,Y yields additive doses
relative to the components’ effective concentrations XI,YI at ILoewe. (C) Bliss
boosting describes combinations with a variable boost b above Emax (the greater
of the single agent limiting efficacies EX,EY), at high combined concentrations.
Useful reference levels for Bliss boosting are ‘cancelling’, ‘suppressing’,
‘masking’, ‘multiplicative’ corresponding to Bliss independence (Bliss, 1939),
and ‘saturating’ (see Materials and methods). Finally, (D) potentiation can
characterize responses similar to those of Bactrims (Figure 1), where one single
agent’s curve IX(C) is shifted with a power-law slope p above an enhancer
concentration Ypot, and superposed on the enhancer’s own activity. These
models can be extended to higher-order combinations, and used in the same
form (with adjustments to Bliss boosting) for any type of measurement, provided
that the activities of both agents vary monotonically with concentration. Of these
models, only Loewe additivity has an a priori mechanistic basis.
Chemical combinations and target connectivity
J Leha´r et al
& 2007 EMBO and Nature Publishing Group Molecular Systems Biology 2007 3
degenerate, or indistinguishable, shapes for some parameter
settings), and also are not complete, in that some observed
surfaces do not fit any of them. Nevertheless, this set does
cover many of the observed effects in our therapeutic screens,
and permits a quantitative exploration of different synergy
types. Each observed dose matrix can be analysed by fitting
all the shape models to the data by means of least-squares
minimization across any free parameters, and determining
which shape models produce consistent fits. It is also useful to
calculate a volume VHSA between the data and the HSA surface,
normalized to the concentration sampling, to characterize the
overall strength of combination effects.
Simulations of metabolic pathways
We used numerical simulations of metabolic pathways to
show that pairs of targets with differing connectivity produce
distinct combination effects (Figure 3). We constructed a
branched, unregulated pathway of linked Michaelis–Menten
reactions (Supplementary 1), and computed the inhibition of
final reaction velocity after applying varying concentrations of
paired competitive enzymatic inhibitors (affecting Km). Each
pair of inhibitors was applied repeatedly over a dosing matrix,
and we determined the response morphology by fitting our
shape models to each simulated dose matrix, and finding
which shape provided the best match over the whole surface
(Figure 3). We found that when both inhibitors targeted the
same enzyme, Loewe additive surfaces were produced as
expected. When the inhibitors had separate targets within this
pathway, the resulting surfaces were best fit by Bliss boosting,
with differing levels depending on the target connectivity.
These differences in combination effect were robust to
plausible variations of the simulated pathway that did not
affect the network topology. Random perturbations of up to
two orders of magnitude in all the reaction parameters
recovered the original best-fit shapes (Supplementary Figure
S2), suggesting that the response morphology is affected by
only such extreme changes in kinetic parameters that alter the
network topology. Similar Monte Carlo simulations perturbing
specific parameter classes or individual enzymes showed no
strong sensitivities to particular kinetic parameters or targets
for this pathway (Supplementary 3). Converting the inhibitors
to non-competitive (affecting Vm) kinetics likewise recovered
the original best-fit shapes, altering mainly the single agent
curves. An exception is that unbypassed serial combinations
(e.g., R1xR6; Figure 3) yielded HSA-like responses for non-
competitive inhibitors (Supplementary 2). Adjusting the end
point to something more like proliferation by means of an
exponential transform (see Materials and methods) distorted
the resulting boost levels, but still did not change which shape
model was preferred. All of these factors could strongly affect
the single agent curves (e.g., potency, steepness, and limiting
efficacy) but the best-fit shape model for each simulated
combination effect was very stable to perturbation.
Introducing regulation by negative feedback did have strong
effects on the combination responses. Pathway B was added to
investigate synergy across pathways and to predict effects for
sterol biosynthesis. Whereas inhibitors with serially placed
targets in an unregulated linear pathway produced multi-
plicative boosts, enclosing such targets in a negative feedback
loop yielded strong potentiation (although like unregulated
serial inhibitors, these yield weaker effects for non-competi-
tive inhibitors). The synergies under negative feedback are
not immediately intuitive (Supplementary Figure S3) and an
analytical derivation of the simulated power-law potentiation
for this model would be challenging, underscoring that
simulation is the most practical means for deriving even the
simplest emergent properties of complex systems.
Another change affecting topology is to alter the type of
junctions in a pathway. For the branches in Pathway A, the
reaction could proceed down either side to the end point;
so parallel pairs of inhibitors across these junctions (e.g., R3
with R5) are functionally analogous to logical OR operations.
Inhibiting across such OR junctions produced saturating Bliss
responses in our simulations. Replacing such junctions with
functional AND operations (here implemented by pairing
targets across Pathway A and Pathway B, both required for
RAB) resulted in masking surfaces (close to HSA or Bliss
masking) for combinations that straddled the junction. Such
masking effects were produced even for cross-pathway
combinations involving R11 and R12, which are bypassed in
Pathway B to ensure clear distinctions between masking,
multiplicative, and saturating boosts.
The best-fit shapes for all the combinations in both
simulated pathways are summarized in Figure 4, using
symbols whose size reflects the HSA volume and where the
colour and symbol denote the best-fit model. The ambiguity
between the shape models for each combination is illustrated
in Supplementary Figure S4. In these simulations, the fitted
shapes clearly correspond to distinct mechanistic configura-
tions. It is notable that all the cross-pathway combinations
produced either HSA surfaces or other masking surfaces with
weaker combination effects (with |VHSA|B1, between the
measured effect and the HSA model surface) than are seen
within each of the pathways (|VHSA|B3–10).
These simulations suggest specific hypotheses in terms of
our shape models for experimental combinations of chemical
inhibitors of metabolic pathways. Agents sharing a primary
target should, of course, produce Loewe additive responses.
Branched unregulated pathways should produce various
levels of Bliss boosting, depending on the target connectivity,
and linear pathways regulated by negative feedback should
show power-law potentiation. Combinations with targets that
cross between such pathways are likely to produce masking
effects (similar to the HSA model or Bliss masking).
Yeast combinations experiment
To test some of the hypotheses from our simulations, we
undertook a chemical combination screen focused on the
sterol metabolism in yeast. This pathway is very well
characterized with known inhibitors at a number of enzymes
(Wills et al, 2000), and is regulated by negative feedback
(Gardner et al, 2001). We selected 10 antifungal drugs (Table I),
six with targets along a linear section of the pathway and four
targeting other cellular functions. Because sterol biosynthesis
is much the same across yeast species (Wills et al, 2000), we
selected Candida glabrata, a frequent focus of antifungal
treatment that we had used in past therapeutic screens, and
measured proliferation using a metabolic assay (Materials and
Chemical combinations and target connectivity
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methods). After determining single agent activities for all the
drugs, we designed dose-matrix experiments with concentra-
tion samples centred on each drug’s effective concentration at
50% effect (EC50) when possible.
The dose-matrix responses for each combination are
presented in Figure 5 and Supplementary 4. The combination
effects are visible towards the top right-hand corner of each
response surface, especially between the sterol pathway
inhibitors. Some of the single agents produced variable
responses, and this is most obvious for those drug-with-itself
dose matrices along the diagonal of the grid which show only
one side appearing to be active. The self-combination of
Figure 3 Simulations of a multiply inhibited network yield distinct response shapes that depend on target connectivity. Substrates (black nodes) are metabolized
through a series of Michaelis–Menten reactions (grey circles) from sources with constant reaction velocities to a limitless sink at the end-point. We calculated dose-matrix
inhibitions of the end point velocity at RE to paired competitive inhibitors at various enzymes. The response surfaces for some combinations are shown, with the inhibitors
indicated by joined markers. For Pathway A, same-target pairs produced Loewe additivity, and separated targets led to various Bliss boosts depending on where the
targets were placed. Pathway B was added to investigate combination effects across pathways, with a bypass to ensure clear distinctions between cross-pathway
boosting levels. Because both inputs are required for RAB, the junction is equivalent to a logical AND function. The negative feedback in Pathway B was introduced to
represent processes like sterol biosynthesis in yeast. Inhibiting across pathways produced HSA-like masking effects, and inhibiting within the negative feedback loop
yielded potentiation effects.
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rapamycin illustrates how a spurious synergy can arise from
instability in the measured potency of a drug, and the apparent
synergy of miconazole and itraconazole shows evidence of
single agent instability—its inhibition errors are exceptionally
large, indicating inconsistency between the replicate blocks.
Much more striking are the synergies between sterol inhibi-
tors, which span a greater range of concentrations and which
recapitulate the known antifungal synergy between statins and
azoles (Lorenz and Parks, 1990).
The shape and magnitude of each combination effect is
summarized by symbols whose size represents the total
synergy (as measured by VHSA) and whose colour denotes
the best-fit shape model. Degeneracies between the models are
measured by the comparative chi-squared (w2) goodness-of-fit
estimates (Supplementary 4 and Supplementary Figure S5).
Although the data quality did not permit a clear distinction
between the HSA model and Loewe additivity, the two most
similar models in the set, most of the drug pairs sharing the
same targets and agent-with-self combinations produced
responses that were consistent with Loewe additivity. The
exceptions all had relatively weak synergy, with only one,
Itraconazole with Miconazole, exceeding the estimated sys-
tematic error level (VHSA41; see Materials and methods). By
contrast, all but one of the cross-target sterol combinations
exceeded that level, and all produced surfaces that were best fit
by potentiation. Across pathways, the combination effects
were more variable, and strong synergies (VHSA41; see
Materials and methods) were relatively rare (5/28 versus
10/22 for same pathway), with an B8% Poisson probability
(Press et al, 1997, y14.3.3).
The observed effects confirm predictions from our pathway
simulations. We expected same-target combinations to pro-
duce Loewe additivity and cross-target sterol pairings to give
rise to potentiation. Among the 11 same-target and 11 cross-
target sterol combinations tested, the prediction accuracy
is only 54% if we insist on unambiguously correct shape
classifications (the predicted model has w2min, and Dw
24w2min
for the next best fit). However, almost all the failures are due to
the degeneracy of the models for HSA-like combinations. If we
count as a success any surface whose best fit was indis-
tinguishable from the predicted shape, with Dw2ow2min,
the prediction accuracy rises to 72% with an uncertainty of
B22% due to the sample size, assuming Poisson statistics
within each confusion matrix class. Across pathways, the
relative diversity of combination effects makes sense, because
their target connectivities are probably more varied, and
the relative rarity of strong synergies accords with the
Figure 4 The best-fit shape models for our simulated pathway (Figure 3)
consistently depend on target connectivity. Combination effects between
competitive inhibitors are shown as symbols whose area is proportional to the
HSA volume and whose colour indicates the best-fit model shape: black for HSA,
blue for Loewe additivity, green for Bliss boosting, red for potentiation, and grey
when two or more models could not be distinguished (see Supplementary Figure
S4). The Bliss boosting model is subdivided using shape to indicate the boosting
level (square for saturating, diamond for multiplicative, circle for masking, and
open circle for suppressing). The bold lines separate Pathway A from Pathway B
combinations, and the thin lines partition Pathway A into its component sections.
All inhibitor-with-self pairings fit Loewe additivity, as expected. Other
combinations within Pathway A consistently fit the Bliss model with distinct
boosting levels. Cross-target combinations within the negative feedback in
Pathway B consistently show potentiation, and cross-pathway combinations
always have masking responses (close to Bliss masking, additivity, or HSA).
Table I Drugs used in the C. glabrata proliferation experiment
Drug name Abbrev. CAS number Conc. range (mM) Target function Target gene/protein
Cerivastatin CERV 145599-86-6 0.47–7.6 Sterol synthesis HMG1,a HMG2a
Alendronate ALND 121268-17-5 3.0–48 Sterol synthesis ERG20b
Terbinafine TERB 78628-80-5 1.9–30 Sterol synthesis ERG1c
Fluconazole FLUZ 86386-73-4 2.0–32 Sterol synthesis ERG11d
Itraconazole ITRZ 84625-61-6 0.06–1.0 Sterol synthesis ERG11
Miconazole MICZ 75319-48-1 0.03–0.21 Sterol synthesis ERG11d
Rapamycin RAPM 53123-88-9 6.2–100 Cell signalling TOR1,e TOR2e
Pentamidine PENT 140-64-7 0.53–8.5 Various CDH1,c SDH3,c MRP3c
Amphotericin B AMPT 1397-89-3 0.09–1.4 Cell wall Ergosterol,e ACC1c,e
Caspofungin CASP 162808-62-0 0.06–1.0 Cell wall FKS1f
aRine et al (1983).
bBergstrom et al (2000).
cLum et al (2004).
dGiaever et al (2004).
eTerrell and Hughes (1992).
fDouglas et al (1997).
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predominantly masking effects in our simulated cross-path-
way combinations.
Combination screen in human tumour cells
There is further support for our simulations from a prior
combination screen aimed at discovering potential combina-
tion therapeutics. Human tumour cells (HCT116) were tested
using a proliferation assay for responses to all pairwise
combinations of 90 drugs and probes, most with known
mechanism (Supplementary 5). This screen provides a broad-
er sampling of possible target connectivities than had our
C. glabrata experiment, and permits us to investigate the
applicability of our shape models to cellular signalling
networks. Because this screen had been designed for
discovering potent synergies, a four-fold dilution factor had
been used (compared to two-fold for our yeast experiment),
and many compounds were either inactive alone or had not
been sampled far above their EC50 concentrations, often
obscuring distinctions between fitted shape models. Never-
theless, we expect strong potency shifts to be nearly always
detectable, and other shape classes can be distinguished when
the single agents have been appropriately sampled.
For each combination, we obtained an HSA volume VHSA
and best-fit shapes as described above. We also examined
‘synergy profiles’ constructed from each agent’s VHSA values
across all the other probes, and recorded the correlation
coefficient between the synergy profiles for each pair of drugs
in the screen. Each pair of drugs was classified by target
relatedness, using the known target annotations (Supplemen-
tary 5), as ‘Identical’ for drug-with-itself, ‘Same’ for drugs
sharing a target, ‘Related’ for pairs with distinct targets in the
same pathway or function, ‘Different’ for pairs targeting
distinct functions, and ‘Unknown’ for pairs involving at least
one uncharacterized drug. Inter-kinase combinations were
classified separately as ‘Kinases’. Supplementary 6 presents
the resulting scores and correlations for all the tested
combinations, and Supplementary 7 shows their distributions
grouped by target similarity.
The shape models in Figure 2 provide reasonable coverage
of the observed combination effects. OnlyB30% of 4092 drug
pairs in the screen produced a formally acceptable fit (w2mino2)
to any of the models (Supplementary 7a). However, given the
systematic errors produced by the experimental process
(Materials and methods), a more fair assessment of the
uncertainties can be obtained by examining the w2 distribution
of the Loewe additive model for the 87 drug-with-self
combinations, as a negative control set. These ‘Identical’
combinations have a median additive w2B9, suggesting that
the uncertainties are roughly three times larger than the formal
estimates from replicate dose matrices, due to systematic errors
that were not accounted for by the scatter between replicates.
Adopting this w2 level as more representative of the errors
extends the coverage (w2mino18) of our models to most of the
Figure 5 Validation of expected combination effects in a yeast experiment focused on sterol biosynthesis. In yeast, the sterol pathway (left) produces ergosterol, an
essential cell wall component, through a series of metabolic enzymes (grey symbols) acting on intermediate substrates (black symbols), and regulated by negative
feedback (dotted connections). The experiment tested C. glabrata proliferation responses to all combinations of 10 antifungal drugs (Table I), six with known targets on
the sterol pathway (inhibitor markers). The results are shown (centre) with concentrations increasing from the bottom left of each drug pair’s dose matrix. The
combination effect symbols (right) summarize the observed response for each pair in terms of the models presented in Figure 2. Size shows synergy as measured by
VHSA, the volume between the data and HSA surface. The best-fit shape model is indicated by colour: black for HSA, blue for Loewe additivity, green for Bliss boosting,
red for potentiation, and grey when two or more models could not be distinguished (see Supplementary Figure S5). Drug pairs sharing a target mostly produced weak
responses (VHSAo1) consistent with Loewe additivity, and cross-target sterol combinations produced potentiation, as expected for a linear pathway under negative
feedback (B70% prediction accuracy). Combinations involving non-sterol drugs showed fewer strong combination effects and their synergy profiles across all the drugs
were more variable.
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screen, leaving only B10%, which are dominated by those
combinations that are equally inconsistent with all four models.
For an analysis of the observed shape distributions, we
selected a set of ‘optimally sampled’ combinations, where at
least two concentration samples had been tested above the
EC50 for both single agents, enabling distinctions between
strong combination effect shapes. Among these 253 combina-
tions, B60% fit masking models (HSA, additive, or Bliss
masking), B30% were best fit by potentiation, with the
remainingB10% accounted for by multiplicative or saturating
Bliss boosts. These proportions hold even for the 91 optimal
combinations with sub-saturated single agent activities
(Emaxo90%), for which masking and multiplicative effects
would be clearly distinguishable. For all target connectivity
groupings, the optimally sampled combinations were domi-
nated by masking and potentiation effects.
Across the whole screen, combination effects and synergy
profile correlations (Figure 6A and B) support the trends
observed in our pathway simulations and the C. glabrata
experiment. When we examined synergy score distributions
(Supplementary 7), we found that drug pairs targeting
different pathways or involving unknown targets had sig-
nificantly more variable scores (Materials and methods) with
a slight trend to lower synergy levels. The synergy profile
correlations show a more striking trend. Pairs with the same or
related targets ought to have similar connectivities with the
rest of the set, because they are likely to have similar
mechanistic relationships to the rest of the drug targets in
the screen. Indeed there are significant differences between the
profile correlation distributions with a stronger trend towards
increasing correlation with target similarity.
The responses to pairings of kinase inhibitors also provide
support for an association between combination effects and
connectivity. Whereas combinations between kinases in
general had similar distributions to those for other related
target pairs, combinations between drugs targeting the
phosphatidylinositol-3 kinase (PI3K), protein kinase C
(PKC), or mitogen-activated protein kinase (MAPK) signalling
pathways (Table II) showed exceptionally strong synergies and
correlations. HCT116 cells maintain an activating KRAS
mutation that drives cellular growth and survival (Shirasawa
et al, 1993), and are especially reliant upon epidermal growth
factor receptor (EGFR)-mediated signalling for proliferation
(Awwad et al, 2003). Because these pathways are central
to EGFR signalling and interconnected (Schlessinger, 2004),
we would expect HCT116 cells to be very sensitive to these
combinations, and that inhibitors of those pathways should
have similar synergy profiles. Moreover, the combination
effects between the pathways show differences (Figure 6C)
that are consistent across mechanistic replicates, despite
limited concentration sampling and evidence of secondary
target activity. Such differences may eventually provide novel
insights into how these pathways interact in the context of
HCT116 proliferation (e.g., that the MAPK/PKC connection
may be less direct than the other target pairings).
Discussion
The simulations and experiments presented here add a new
dimension to earlier studies investigating the effects of
multiple perturbations to biological systems. Early studies of
statistical epistatic associations between random mutagenesis
Figure 6 Combination effect statistics from the HCT116 screen show expected trends, and the exceptionally strong synergies between inhibitors of EGFR signalling
(Table II) reflect known connections. The distributions of HSA volumes (A) and synergy profile correlations (B) are shown for drug pairs in the HCT116 tumour cell
screen (Supplementary 6), grouped by target similarity (‘Identical’ for drug-with-self combinations; ‘Same’ for distinct drugs sharing a target; ‘Related’ for differing targets
sharing a common functional group; ‘Different’ for pairs with different functions; and a separate group ‘Kinases’ for combinations between kinase inhibitors). There is a
significant trend towards more variable synergy and lower profile correlations for more distantly related targets (Supplementary 7), and the most synergistic and highly
correlated pairs within the ‘Kinases’ set are dominated by those targeting the EGFR signalling pathways, which are major drivers of HCT116 proliferation. (C)
Combinations between MAPK/PI3K, MAPK/PKC, and PI3K/PKC targets show different levels of response that are consistent across mechanistic replicates, despite
limited concentration sampling (only TUBC and ROTT were optimal) and evidence of off-target effects (synergy between PI3K inhibitors and discrepant ROTT effects
compared to the other PKC inhibitors). Shape model degeneracies are shown in Supplementary Figure S6.
Chemical combinations and target connectivity
J Leha´r et al
8 Molecular Systems Biology 2007 & 2007 EMBO and Nature Publishing Group
and chemical stresses (Elena and Lenski, 1997; Kishony and
Leibler 2003) were followed by systematic studies of mutant
libraries in combination with chemical probes (Giaever et al,
2004; Lum et al, 2004; Parsons et al, 2004) and synergies
between targeted chemical probes (Haggarty et al, 2003; Yeh
et al, 2006). This study explores the additional information
available from variable dose response matrices, and relates
quantitative combination effects, as measured response shape
classification or by HSA volumes, to target connectivity. We
use the term ‘connectivity’ to capture both the distance and
topology of the connection between the targets, rather than the
more common ‘interaction’ (Parsons et al, 2004), denoting the
presence of a functional connection. Our pathway simulations
show that biological systems are expected to produce a useful
variety of combination effects that are correlated with
connectivity, and our experimental results demonstrate that
the simulations are biologically relevant and predictive.
There was only partial consistency between specific
chemical synergies in our yeast experiment and corresponding
interactions observed in earlier genetic screens (Supplemen-
tary 8). The observed synergies between sterol inhibitors are
reflected in homozygous synthetic lethalities (Stark et al,
2006) that are internal to the pathway, and rapamycin’s
synergy with terbinafine agrees with the reported interaction
between TOR1 and ERG1. However, the mutant screen of
caspofungin’s target, FKS1, showed no correlation with our
combination effects. Moreover, there is little correspondence
between our results and the cross-activities identified in drug
sensitivity screens of heterozygous yeast mutants (Giaever
et al, 2004; Lum et al, 2004; Parsons et al, 2004). The mixed
results of these comparisons are not very surprising. Aside
from experimental errors (see Materials and methods), some
of the disagreement can be ascribed to the quantitative nature
of dose-matrix response data, because the responses to
varying doses (Hartman and Tippery, 2004), or even time-
resolved experiments (Warringer et al, 2003), can detect the
effects of non-essential genes that would have been missed in
lethality screens. Another contribution may come from likely
differences between genetic and protein networks (Ozier et al,
2003). Chemical combinations can interfere directly with
protein interactions without mediation through gene expres-
sion, and although the protein and gene networks are
intertwined, connectivity differences between the two types
of targets should be expected.
There was more agreement between our simulation results
and a prior flux balance analysis (FBA) of the yeast metabolic
network (Segre` et al, 2005) in response to paired mutations.
The simulated mutations should correspond roughly to the
high-concentration limit of our dose matrices. Both ap-
proaches predict strong synergies (synthetic lethality) when
the system is inhibited across parallel alternative pathways,
and find masking effects (buffering) when unrelated pathways
are impaired, provided that the two pathways are not
competing for a common supply of precursors (Supplementary
Figure S2 in Segre` et al). The main difference is that the FBA
simulations produced more multiplicative than masking
pairings, especially for cross-pathway combinations. This
may be due to the partial view of combination effects provided
by the epistasis scores (Supplementary Figure S1), or to an
implicit assumption, in the FBA simulations, that competition
for the same metabolic ingredients is widespread. The
masking responses found in our cross-pathway simulations
are supported experimentally, by the weaker synergy levels
seen in our C. glabrata experiment, and by the large fraction of
masking effects (B60%) in both the HCT116 screen and prior
antibacterial combination experiments (Yeh et al, 2006).
Thus the dose-matrix response shapes and synergy profiles
from systematic combination screens can provide valuable
new insights into network connectivity. A possible application
in chemical genetics would be to extend phenotypic profiling
for mechanism inference (Perlman et al, 2004; Macdonald
et al, 2006), using combinations effectively as extra assays.
Query drugs with unknown targets could have their synergy
profiles compared to a previously assembled profile library for
a diverse set of chemical probes. The known targets for those
probes whose profiles correlate most closely with a query
drug’s are likely candidates for the drug’s mechanism. For
constructing biological network models, observed combina-
tion effects can be compared to expectations from target
connectivity through existing protein interaction networks,
and inconsistencies can be used to improve the models by
means of a prediction-validation procedure (Ideker et al,
2001). Combining chemicals is much simpler than the process
of constructing double mutant strains, and chemical combina-
tions can yield detailed information about connections
between proteins that are not accessible to single agents or
mutagenesis, enabling the study of disease networks like those
involved in cancer (Schoeberl et al, 2002) and inflammation
(Bouwmeester et al, 2004) signalling.
Of course, there are limitations to this approach for probing
biological networks. The collection of full dose matrices is
expensive, and will necessitate a trade-off between the added
information obtained from response shapes and the loss of
assay fidelity from the use of high-throughput measurements
(e.g., single time points for growth rather than time-resolved
growth curves). The mechanistic information that can be
extracted will depend strongly on the generality and specificity
of the set of shape models being used. The four models
presented here represent only a subset of the observed
responses, and the pathway simulations sampled only a small
minority of possible target connectivities. Even with more
Table II Drugs targeting EGFR signalling used in the HCT116 proliferation
experiment
Drug name Abbrev. CAS number Conc.
Range (mM)
Target kinase
U-0126 U0126 109511-58-2 0.10–26 MAPK/MEKa
5-iodotubercidin TUBC 24386-93-4 0.04–10 MAPK/ERKb
LY 294002 LY294 154447-36-6 0.13–33 PI3-Kc
Wortmannin WORT 19545-26-7 0.09–23 PI3-Kd
GF 109203X GF109 133052-90-1 0.08–21 PKCe
Ro 31-8220 RO-31 138489-18-6 0.04–9.8 PKCf
Rottlerin ROTT 82-08-6 0.08–19 PKCg
aFavata et al (1998).
bFox et al (1998).
cYano et al 1995).
dOkada et al (1994).
eToullec et al (1991).
fDavis et al (1992).
gGschwendt et al (1994).
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extensive simulations, there will certainly be mechanistic
degeneracies associated with each distinct response shape. For
example, it will probably be possible to produce potentiation
like that seen in Bactrim using several distinct target
configurations. Thus, response shapes cannot be used to
uniquely define combination mechanisms, but merely to
exclude inconsistent connections. Finally, chemical probes
often have poorly characterized mechanisms or multiple
targets, and combination screens will have to account for this
by covering biological targets with several chemically distinct
probes. Despite all these limitations, the present study has
shown that even with a limited set of shape models, dose-
matrix data can provide useful connectivity information.
The results of this initial exploration suggest several
directions for expanding the response surface approach to
combination analysis. First, it is essential to extend the current
shape model set by using more comprehensive simulations of
larger networks. The most obvious way to do this would be to
define a basis set that represents simple observed network
connectivities, including serial and parallel arrangements,
bifurcations, both AND and OR junctions, and some regulation
mechanisms (Milo et al, 2002). Combination responses from
pathway simulations covering the connectivity basis could
then be used to define shape models for comparison with
simulated responses for larger networks, as well as with
experimental data. Another approach would be to system-
atically explore perturbations of an existing biological net-
work, such as S. cerevisiae metabolism (Famili et al, 2003), and
to model drug inhibition by partially restricting the reaction
rates at metabolic enzymes, essentially the Segre` et al’s FBA
for partial inhibitors. The challenge with this approach would
be to identify meaningful connectivity measures that correlate
with simulated synergy types. A third very promising area for
future exploration is higher order combinations. The emer-
gence of resistance to treatment for afflictions like cancer (Fojo
and Bates, 2003) can be effectively addressed by combinations
of three or more drugs (Komarova and Wodarz, 2005).
Combination approaches can also offer improved control by
perturbing multiple components of the disease network
(Csermely et al, 2004), and higher order combinations should
provide yet more details on mechanistic connections between
their targets. The response surface approach presented here
can be readily adapted to three or more drugs, as can the
specific shape models shown in Figure 2, and a metabolic FBA
of higher order combinations should provide important
insights into the effectiveness of multi-target treatments.
Finally, because the simulated combination responses were
insensitive to the reaction details, this methodology may even
be extendable to non-biological network problems where
responses to targeted perturbations can be measured (Milo
et al, 2002).
Materials and methods
Combination response shape models
Experimental dose-matrix responses include both potency shifts,
where a combination alters the apparent potency of the single agents,
and efficacy boosts, where the joint effect exceeds levels possible for
either of the constituents. Many of these responses can be described by
simple models that use the single agent curves to predict the
combination effect (Figure 2), and whose parameters provide
quantitative measures. Strong potency shifts relative to a simple HSA
surface can be described using a power-law potentiation model, and
efficacy boosts are quantifiable using a model that extends Bliss
Independence (Bliss, 1939) to variable combination effect levels at
high concentration. These models are expressed in terms of inhibi-
tions, but can be adapted to other types of measurement, or for
combinations involving more than two perturbing agents, without
altering their qualitative properties. The shapes presented are not a
complete orthogonal set covering all expected combination responses,
but were chosen to represent some of the variety seen in our
therapeutic screens, as well as to reflect historical reference models
used in the literature.
The HSA model, or Gaddum’s non-interaction (Berenbaum, 1989),
is based simply on the intuition that if a combination’s effect exceeds
those of its constituents, there must be some interaction. Mathema-
tically, the HSA model is a superposition of the single agent curves
where, at any combined concentration (X,Y), the inhibition
IHSA¼max(IX,IY), where IX and IY are effects produced by the single
agents at (X,0) and (0,Y). The model values are calculated at each dose-
matrix point, where IX and IY were determined using sigmoidal fits to
the single agent response data. The volume VHSA¼SX,Yln fX ln fY(IdataIHSA)
between the data and the HSA surface, adjusted for variable dilution
factors fX, fY, can be readily calculated and provides a practical
overall measure of synergy (in units of inhibition), summed over
dimensionless log-concentration space.
We also considered Loewe additivity (Loewe, 1928), the drug-with-
itself standard. At each combined concentration (X,Y), we used
an iterative approach (Berenbaum, 1985) to find the inhibition ILoewe
that satisfies (X/XI)þ (Y/YI)¼1, where XI and YI are the single agent
effective concentrations. Starting with a guess that I¼IHSA, we
interpolated the single agent curves to find XI,YI that produce I,
calculated the corresponding combination index, and used bisection
(Press et al, 1997) to converge on a value of I with combination index
CI¼1. Loewe additivity reduces to HSA at concentrations that are very
different from XI,YI, as well as for I above an agent’s limiting activity
(effectively XI,YI-N).
To model boosts in efficacy at high concentrations different from
what the single agents can achieve, we used a ‘Bliss boosting’ model,
adapting the Bliss independence model (Bliss, 1939) for boost levels
other than multiplicative. Mathematically, IBliss¼IXþ IYþ (bEmin)(IX
IY/EX EY), where Emin is the lesser of EX and EY, the limiting single agent
efficacies. The one free parameter b, in units of effect, determines the
amount of boosting above Emax, the greater of the single agent
efficacies. For inhibition effects, there are a number of useful reference
levels: b¼Emax produces ‘cancelling’, with zero effect at high
concentration; b¼EminEmax is ‘suppressing’, where the less effective
agent prevails; b¼0 yields ‘masking’, where the more effective agent
prevails; b¼Emin(1Emax) is multiplicative (Bliss independence); and
b¼(1Emax) produces ‘saturating’ at 100% inhibition. At the high
concentration limit, the suppressing, masking, multiplicative, and
saturating levels correspond to ‘suppression’, ‘buffering’, ‘no epista-
sis’, and ‘synthetic lethal’ in recent classifications for epistasis (Elena
and Lenski, 1997; Segre` et al, 2005; Yeh et al, 2006). Bliss boosting can
be used in this form for any type of effect measure provided that the
single agent responses increase monotonically with concentration.
Only the saturating and multiplicative reference levels need to be
adjusted according to the measurement scale. For example, if we
consider fitness ratios (treated over untreated growth ratios) with
f¼ln(T/U) in place of inhibitions, there is no saturating level and
b¼Emin indicates multiplicative. Note that Bliss masking is similar to
both HSA and Loewe additivity for very high or very low concentra-
tions where the single agent effects are almost flat.
Finally, we used a power-law ‘potentiation’ model to describe strong
shifts in potency similar to that seen for Bactrims (Figure 1). For such
combinations, an active single agent’s response curve shows an
increase in potency as the enhancer is titrated in, which is seen as
linear iso-effect contours in serially diluted dose matrices (logarithmic
concentration space). The inhibition IPotent¼max(IX(C), IY), where
IX(C) is the single agent response curve of the potentiated compound,
at a shifted concentration C¼X[1þ (Y/Ypot)|p|]sign(p), where sign(p) is a
unit sign function evaluated at (1, 0, þ 1) corresponding to the sign
of its argument. Although the functional form presented here is
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awkward, it was the simplest way we could find to achieve power-law
potentiation and depotentiation above a threshold enhancer concen-
tration, with the enhancer’s own activity superimposed. The two free
parameters for this model are the threshold concentration Ypot above
which potentiation takes effect, and the potentiation slope p (synergy
for positive and antagonism for negative p). There is no potentiation
for p¼0, where this model reduces to an HSA surface. Just as for HSA
and Loewe additivity, the form of this model is identical for any type of
effect measure.
These models are not orthogonal; so we defined a fitting order to
ensure an unambiguous choice. The shape models have degeneracies
where two or more models can describe similar response shapes.
Loewe additivity and HSA, for example, are largely degenerate, in that
only when the single agents increase slowly over the sampled
concentrations can a distinction between the two models be made.
Nevertheless, both can be readily distinguished from Bliss boosting
and potentiation, which themselves are distinct over a large range of
their parameters, and many observed surfaces fit only one model
effectively (Supplementary 2). To ensure an unambiguous choice that
applies the principle of Occam’s razor when fitting several models to
an observed surface, we ordered them by increasing complexity (HSA,
Loewe, Bliss, potentiation) and declared as best fit the first model that
was consistent with the observed surface. Within Bliss boosting, we
classified combinations as cancelling, suppressing, masking, multi-
plicative, or saturating, depending on which fell closest to the best-fit b
for the observed response shape. Note that for some pairings, the boost
levels cannot be separated. For example, if one single agent reaches
100% inhibition at high concentration, it will be impossible to
distinguish saturating from multiplicative or masking levels. If both
single agents reach 100%, only cancelling effects will be distinguish-
able from the others. For such boost level degeneracies, the first
consistent level in the sequence above was chosen.
We note that these models were used primarily to characterize
response surface shapes. Indeed, of the four shape models discussed
here, only Loewe additivity has an a priori physical foundation as a
predictive combination model. Although the original Bliss indepen-
dence model (corresponding to the multiplicative level of Bliss
boosting) is based on statistical independence, that foundation has
no clear relevance to biological systems, where widely separated
targets are neither statistically independent nor cleanly competing for
the same end point. The Bliss boosting and potentiation models were
included in our analysis to describe distinct shapes observed in our
screens, and for well-sampled dose matrices neither is very good at
fitting the effects that the other was designed to describe.
Pathway simulations
Simulations of metabolic pathways were performed using the XPPAUT
ordinary differential equation simulation software (Ermentrout, 2002),
on Boston University’s Biowulf computing cluster. The network shown
in Figure 3 was modelled as a system of Michaelis–Menten enzymatic
reactions, each with three kinetic parameters: the limiting reaction rate
Vm, the rate constant Km, and an exponential degradation rate Dg. The
two pathways were driven by supplying substrates S1 and S11 from
limitless sources with constant reaction velocities, and converting
them through the enzymatic reactions before passing through the end-
point reaction RE into a limitless sink. For symmetry and simplicity, we
set all Vm¼1 and Km¼1, and the degradations Dg to a lower level of 0.01
in most cases. We used Dg¼1 for substrates at bifurcations and for the
final product of Pathway A to ensure illustrative differences in the
single agent inhibitions (reducing response shape degeneracies) and to
balance the flux through both pathways (for stable simulations). The
system was initially started with all substrate levels set to 0.1 and run
to steady state using an RK4 integration algorithm calculated at time
intervals of 0.001 over 1000 000 iterations, and the resulting substrate
levels and parameter settings are shown in Supplementary 1. The
combination response for each pair of inhibitors was determined using
100 simulations over a 1010 dose matrix, where for each dosing
point the targeted reactions were restricted by competitive inhibitors
(that affect Km) and the simulation was run for a further 600 000
iterations using a step size of 0.005, before the inhibition I¼1–T/U was
calculated on the treated end-point reaction velocity T, relative to the
untreated velocity U. Optimal 9-point inhibitor concentration samples
were chosen for each single agent by using a bisection search to find
the single agent’s EC10 and EC90 concentrations, defining six samples
with a fixed dilution factor f¼(EC90/EC10)0.2 to cover that range,
and extending the total range with two additional concentration
steps above the EC90 and one more below the EC10 at the same dilution
factor f.
The resulting combination response data are tabulated in Supple-
mentary 2. Each surface was compared to the models presented
in Figure 2 (assuming 1% inhibition errors), and the best fit was
determined to be HSA, Loewe additivity, Bliss boosting, or potentia-
tion, in that order, depending on which was first consistent with the
best-fitting model’s w2 (where consistency meant that its w2 was less
than twice the best fit’s). Bliss boosting models were further classified
as cancelling, suppressing, masking, multiplicative, or saturating,
where it could be uniquely specified given the single agent limiting
efficacies. The shape classifications, chi-squared, and best-fit para-
meter values are listed in Supplementary 2, and the shapes are also
summarized in Figure 3. Supplementary Figure S1 compares the shape
classifications and target connectivities from this simulation to
epistasis calculations (Segre` et al, 2005; Yeh et al, 2006) based on
single concentration points taken from the matrices.
We varied the model parameters to explore the sensitivity of our
results to the kinetic parameters. First, we performed Monte Carlo
tests with 100 simulations, each time allowing all of the parameters
to randomly vary with uniform probability density within a multi-
plicative range 107D, and counted how often the best-fit model surface
agreed with the original fit before perturbation (Supplementary Figure
S2). The Monte Carlo tests were repeated with steadily increasing D, to
determine the level at which the unperturbed simulations failed
to predict the outcome, both with all Vm, Km, and Dg varied
simultaneously, and with each parameter class perturbed separately.
Finally, we explored sensitivity to individual nodes by perturbing each
enzyme in Pathway A separately.
We also explored some simulation assumptions to test the
robustness of our results. First, we replaced the competitive inhibitor
kinetics with non-competitive (affecting Vm) inhibition, performed the
simulations, and repeated the model fitting to determine the best-fit
response shapes. Second, we addressed the concern that a metabolic
reaction velocity might provide a poor comparison to proliferation, the
most accessible experimental end point. As proliferating cells undergo
exponential doubling, a linear reduction of velocity by a factor T/U for
a growth-limiting metabolic reaction should slow the doubling time
by a proportional factor. Over a time interval corresponding to n
uninhibited doublings, the resulting inhibition of cell population
becomes IgrowthB1–2
nIv, in terms of the velocity-based inhibition IV.
We applied this transformation to our simulated dose-matrix inhibi-
tions for Pathway A, assuming nB10 doublings, and repeated the
surface fitting procedure on the transformed dose matrices to
determine the best-fit response shapes.
Combination screening experiments
The chemical library was archived in robotically accessible vials, to
which diluent (dimethyl sulphoxide or water) was added in prepara-
tion for addition to 384-well master plates by a Tecan Freedom liquid-
dispensing robot. Liquid transfers to dilution and assay plates were
handled using a Perkin-Elmer MiniTrak station adapted for the
combination high-throughput procedure. Each 384-well assay plate
contained six 6 6 dose-matrix blocks, with four serial dilutions (two-
fold for yeast and four-fold for HCT116) of the top concentration for
each agent. Additional wells were reserved for transfer and untreated
control wells. The compound mixtures were then added to the
biological component of the assay as appropriate.
For the yeast experiment, C. glabrata (ATC #90030) cultures were
cultured overnight in flasks with RPMI media in a 321C shaker at
250 r.p.m. The next day, the cultures were diluted into media until they
had an absorbance equivalent to 50% of McFarland standard,
corresponding to a density of B8000 cells/ml, and dispensed with
automated dispensers into 384-well assay plates (35ml wells contain-
ing media and test compounds) to yield B160 cells/well. The plates
were incubated in the presence of drugs and media at 321C for 18 h
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(B10 doublings). Upon completion, cell populations were measured at
a single time point, with a metabolic Alamar Blue fluorescence reagent
(at 590 nm emission) using a Perkin-Elmer Fusion plate reader after
excitation at 535 nm.
For the tumour cell line experiment, the HCT116 (ATC #CCL-247)
cells were cultured in flasks with RPMI-1640 media for 2–20 passages,
drawing test populations along the way. Extracts were trypsinized,
counted, and seeded into 384-well plates at a density of 1500 cells/well
in 35 ml media using automated dispensers. To ensure adherence, the
plated cells were incubated at 371C, with 5% CO2 overnight, after
which the compounds were added and the plates were incubated again
at 371C with 5% CO2 for 72 h (or about 2–3 doublings). After
incubation, 10.5% Alamar Blue fluorescence dye (in 40 ml media) was
added and plates were incubated for 6 h. Cell population measure-
ments were made at a single time point upon completion, using
a Perkin-Elmer Victor II plate reader (excitation at 535/590 nm
emission).
This experimental procedure has a variety of sources for error in
final proliferation measurements. Each compound is dissolved once in
a single stock tube, and delivered into X- and Y-diluted master plates.
Aliquots are then transferred from the master plates to each assay
plate to produce the combinations. While this approach permits
orthogonal serial dilutions and aids uniformity across instances
of each master plate, there can be systematic errors in compound
plating between the X and Y masters for less stable compounds. Cells
are seeded in media at high densities, to reduce the well-to-well
variability, but occasional clogs in a pipette can lead to non-uniform
distribution. During incubation, slight variations in temperature or
humidity can lead to varying growth rates across wells on a plate
and between plates. Because the single cell population measurement
is made during the exponential growth phase, variations can
be amplified in the final readout, and this variation can be exaggerated
when cells are sensitized by test compounds. The result of
these various factors is that cell population measurements vary by
B1–3% on each plate, across untreated wells, and the variations do
not fit a normal distribution. Moreover, some 1–2% of wells on each
plate show occasional spikes that are very different from their
neighbours.
The contents of each plate were tracked in an automated laboratory
information management system, using integrated barcode scanners
in the liquid handling equipment, and stored in an Oracle database.
Plates lacking compound transfers or with insufficient dynamic range
(signal-to-noise ratio o5 between untreated controls and a cell-free
background) were rejected and repeated. The remaining plates were
inspected using custom quality control software. Individual wells that
fell outside the expected range for normal assay readouts, or which
were discontinuous with their neighbours, were marked for exclusion.
Finally, the single agent wells in each combination block were visually
inspected for consistency across the experiment, and combination
blocks containing the most discrepant single agents were marked
for exclusion.
Data analysis
Dose matrices were assembled from replicate combination blocks on
experimental plates. Some of the data showed systematic variations
across the plate, most likely owing to temperature or humidity
gradients during incubation. In order to correct these effects, our assay
plates had 40 untreated wells arranged around and between the
blocks. The systematic variations were removed by fitting a smooth
function of plate location to the untreated well data values, and
dividing out the modelled spatial variation. After plate effect
correction, fluorescence counts T from each treated well were
converted to inhibitions Idata¼(UT)/U relative to the median U of
20 untreated wells. Replicate blocks for each dose matrix were merged,
using the median inhibition at each dosing point. Standard error
estimates sdata for each median inhibition were also calculated, based
on the quadrature sum of a minimum acceptable 3% error, the median
absolute deviation (MAD) of the corrected untreated data on each plate
normalized to their median, and the MAD between replicate inhibition
data between plates, using an empirical conversion from MAD to
standard deviations (Filliben, 2005).
Each dose matrix was scored for synergy, and combination effects
were compared to our response morphology models (Figure 2).
Sigmoidal dose responses I¼ECa/(SaþCa) as a function of concentra-
tion C were fitted to the single agent data, where E is the limiting
efficacy at high concentration, S is the effective concentration, and a is
the sigmoidicity or steepness of transition. These fitted curves were
used for combination effect models. The HSA, Bliss boosting, and
potentiation models were calculated, and the Loewe additivity model
was solved at each dosing point by iterative root finding (Berenbaum,
1985). As a quantitative estimate of the combination activity, we
computed HSA volume excess scores VHSA¼
P
X,Y ln fX ln fY(Idata–IHSA),
summed over all CX,CY, along with an associated error estimate
sHSA¼sqrt[
P
X,Y ln
2 fX ln
2 fYs
2
data], both expressions using adjustments
to account for differing dilution factors fX, fY. This volume measures
the total excess inhibition, summed over dimensionless log-concen-
tration space. Data surfaces were compared to the shapes presented
in Figure 2 by varying the model parameters, using a Nelder-Mead
simplex algorithm (Press et al, 1997, y10.4) to minimize
w2¼Sdata[(Idata–Imodel)/sdata]2/Ndata, the reduced chi-squared. All four
models were explored, and the overall best fit with the least chi-square
w2min was chosen to represent the shape of the combination. A best fit
was chosen from HSA, additivity, boosting, or potentiation, in that
order, depending on which was first consistent with the w2min
(Dw2ow2min).
Finally, systematic errors that were not captured by our error
estimates from replicates can be estimated by examining the drug-
with-self combinations as a negative control for combination effect.
For both screens, the median Loewe additivity w2 wasB9, suggesting
that the true reproducibility of drug response was roughly three times
the estimated levels from the scatter between replicates. This suggests
systematic errors of B10% at each dose-matrix point, leading to
integrated volume error estimates of sHSAB0.4. Thus, only combina-
tion effects with VHSA41 are strong enough to be reliably distinguish-
able from drug-with-itself combinations.
For the HCT116 combination screen, synergy profiles were
constructed for each drug by collecting into a vector all the VHSA
scores involving that chemical. These profiles were then compared for
all pairs of drugs in the screen by means of the Pearson correlation
coefficient. The synergy profile correlations and synergy scores were
grouped by the target similarity (Supplementary 5) of the two drugs in
each combination, and classified as follows: ‘Identical’ for drug-with-
itself; ‘Same’ for distinct drugs inhibiting the same target; ‘Related’ for
differing targets sharing a common functional group; ‘Kinases’ for
combinations of kinase inhibitors; ‘Different’ for unrelated pairs of
drugs; and ‘Unknown’ for pairs involving one or more unknown
mechanism. The target similarity group distributions were compared
for significant differences using a chi-square test that assumes only
Poisson counting statistics within each bin in the histograms (Press
et al, 1997, y14.3.3).
Supplementary information
Supplementary information is available at the Molecular Systems
Biology website (www.nature.com/msb).
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